Patents Assigned to LARIX BIOSCIENCE, LLC
-
Publication number: 20210292384Abstract: Disclosed herein are ACE2 fusion proteins that can be used to block infection of cells by SARS-CoV-2. The fusion proteins may have additional functionality such as inhibition of complement. The fusion protein may also include a polypeptide or a moiety that increases serum or blood half-life of the ACE2 fusion protein.Type: ApplicationFiled: March 19, 2021Publication date: September 23, 2021Applicant: Larix Bioscience LLCInventors: Bo Yu, James Larrick
-
Patent number: 11060083Abstract: The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.Type: GrantFiled: May 19, 2017Date of Patent: July 13, 2021Assignee: Larix Bioscience LLCInventors: Bo Yu, James Larrick
-
Publication number: 20210108190Abstract: The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.Type: ApplicationFiled: May 19, 2017Publication date: April 15, 2021Applicant: LARIX BIOSCIENCE, LLCInventors: Bo Yu, James Larrick
-
Patent number: 10816548Abstract: The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by FACS or MACS. A switching mechanism can be used to delete the reporter from the chromosome by providing an appropriate DNA recombinase, which turns the selected cells into production cells that secrete the protein of interest without co-expression of the reporter.Type: GrantFiled: February 19, 2018Date of Patent: October 27, 2020Assignee: Larix Bioscience, LLCInventors: Bo Yu, James Larrick
-
Publication number: 20180334665Abstract: The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.Type: ApplicationFiled: May 19, 2017Publication date: November 22, 2018Applicant: LARIX BIOSCIENCE, LLCInventors: Bo Yu, James Larrick
-
Publication number: 20180313834Abstract: The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by FACS or MACS. A switching mechanism can be used to delete the reporter from the chromosome by providing an appropriate DNA recombinase, which turns the selected cells into production cells that secrete the protein of interest without co-expression of the reporter.Type: ApplicationFiled: February 19, 2018Publication date: November 1, 2018Applicant: Larix Biosciences LLCInventors: Bo Yu, James Larrick
-
Patent number: 9910038Abstract: The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by FACS or MACS. A switching mechanism can be used to delete the reporter from the chromosome by providing an appropriate DNA recombinase, which turns the selected cells into production cells that secrete the protein of interest without co-expression of the reporter.Type: GrantFiled: November 27, 2013Date of Patent: March 6, 2018Assignee: Larix Bioscience, LLCInventors: Bo Yu, James Larrick
-
Patent number: 9663782Abstract: The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.Type: GrantFiled: July 19, 2014Date of Patent: May 30, 2017Assignee: Larix Bioscience LLCInventors: Bo Yu, James Larrick
-
Publication number: 20150024500Abstract: The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.Type: ApplicationFiled: July 19, 2014Publication date: January 22, 2015Applicant: LARIX BIOSCIENCE, LLCInventors: Bo Yu, James Larrick
-
Publication number: 20140155285Abstract: The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by FACS or MACS. A switching mechanism can be used to delete the reporter from the chromosome by providing an appropriate DNA recombinase, which turns the selected cells into production cells that secrete the protein of interest without co-expression of the reporter.Type: ApplicationFiled: November 27, 2013Publication date: June 5, 2014Applicant: LARIX BIOSCIENCES LLCInventors: Bo YU, James LARRICK